Identification of guanine and adenine adducts in DNA alkylated by DIBROMODULCITOL (cas 10318-26-0) in vitro and in vivo
-
Add time:07/28/2019 Source:sciencedirect.com
DNA reacted with DIBROMODULCITOL (cas 10318-26-0) in neutral solution yielded 3- and 7-alkyl substituted purines after hydrolysis at neutral pH-value at 37°C. The alkylated products were identified by mass spectrometry and by comparison of their UV absorption spectra and chromatographic properties on thin-layer chromatography (TLC) and various columns with those of the corresponding galactitylpurine derivatives obtained by synthetic route from alkylation of the appropriate nucleic bases or nucleosides. The labelled alkylpurines occurring in DNA of Yoshida tumour cells treated with [3H]dibromodulcitol in vivo were also indentified by co-chromatography of labelled DNA hydrolysate with synthetic 3- and 7-alkyl substituted purines. On the basis of the same chromatographic behaviour 3-(1-deoxy-3,6-anhydrogalactit-1-yl)adenine, 7-(1-deoxygalactit-1-yl)guanine, 7-(1-deoxy-3,6-anhydrogalactit-1-yl)guanine and 1,6-di(guanin-7-yl)-1,6-dideoxygalactitol were identified as main alkylated products in tumor cell DNA after in vivo treatment with dibromodulcitol.
We also recommend Trading Suppliers and Manufacturers of DIBROMODULCITOL (cas 10318-26-0). Pls Click Website Link as below: cas 10318-26-0 suppliers
Prev:Facile one-pot sonochemical synthesis of Ni doped bismuth sulphide for the electrochemical determination of promethazine hydrochloride
Next:Adjuvant DIBROMODULCITOL (cas 10318-26-0) and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Metabolism and pharmacokinetics of DIBROMODULCITOL (cas 10318-26-0)(DBD, NSC-104800) in man—II. Pharmacokinetics of DBD08/05/2019
- The effect of DIBROMODULCITOL (cas 10318-26-0) on resting and dividing lymphoid cells08/04/2019
- The distribution of bromine content of DIBROMODULCITOL (cas 10318-26-0) in the central nervous system of patients with malignant gliomas08/03/2019
- DIBROMODULCITOL (cas 10318-26-0), mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer08/02/2019
- APOPTOTIC AND MITOTIC ACTIVITY IN SQUAMOUS CELL CARCINOMA CELLS AFTER COMBINED MODALITY TREATMENT WITH γ-IRRADIATION AND DIBROMODULCITOL (cas 10318-26-0)08/01/2019
- DIBROMODULCITOL (cas 10318-26-0)07/31/2019
- Rat liver-mediated degradation of DIBROMODULCITOL (cas 10318-26-0)07/30/2019
- Adjuvant DIBROMODULCITOL (cas 10318-26-0) and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)07/29/2019